358 reports of this reaction
3.4% of all BUROSUMAB reports
#5 most reported adverse reaction
ARTHRALGIA is the #5 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 358 FDA adverse event reports linking BUROSUMAB to ARTHRALGIA. This represents approximately 3.4% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among BUROSUMAB users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for BUROSUMAB:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 358 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.4% of all adverse event reports for BUROSUMAB, making it a notable side effect.
If you experience arthralgia while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.